The Surveillance of Hepatocellular Carcinoma
Sponsor
Chinese PLA General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05286099
Collaborator
(none)
100
2
23.5
50
2.1
Study Details
Study Description
Brief Summary
Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplastic nodules will be distinguished from early hepatocellular carcinoma through macro-imaging and micro-pathological features.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Surveillance of Development and Progression of Hepatocellular Carcinoma
Actual Study Start Date
:
Jan 15, 2022
Anticipated Primary Completion Date
:
Jul 1, 2023
Anticipated Study Completion Date
:
Dec 31, 2023
Outcome Measures
Primary Outcome Measures
- Effective detection of early hepatocellular carcinoma [2 years]
The occurrence of early hepatocellular carcinoma
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Patients with Hepatitis B and cirrhosis Accept regular imaging examination. Pathological diagnosis of liver cancer.
Exclusion Criteria:
- Can't tolerate the enhanced imaging examination Poor medical compliance
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Chinese PLA General Hospital | Beijing | Beijing | China | 100853 |
2 | Chinese PLA general hospital | Beijing | China |
Sponsors and Collaborators
- Chinese PLA General Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ping Liang,
Chinese PLA General Hospital,
Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT05286099
Other Study ID Numbers:
- S2022-001
First Posted:
Mar 18, 2022
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: